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Huntington disease, Amyotrophic Lateral Sclerosis, Parkinson disease, and Alzheimer 
disease are four multifactorial, neurodegenerative, inheritable disorders affecting thousands of 
people collectively in the United States. The importance of public health measures such as 
support groups for both patients with one of these diseases, as well as caregivers, is high. 
Support groups are beneficial for the patients and caregivers, and are also vital to the well being 
of the patient. Support groups also serve to address important public health services in the United 
States.  
I examined the number of counties with at least one support group available for each of 
these four diseases throughout the central Appalachian region of the United States. First, the total 
number of counties with at least one support group throughout each state in this region was 
assessed and subsequently compared to the number of counties with at least one support group 
within the Appalachian region of each state. The number of counties with at least one support 
group available to individuals living within the Appalachian region of these states was 
significantly lower than the rest of the state (34 vs 61%, respectively, P-value < 0.0001). In 
Appalachia, if the county was economically distressed, it was also significantly less likely to 
contain at least one support group compared to counties that were not economically distressed 
(19 vs 46%, respectively, p-value < 0.0001).  
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My results indicate the presence of health disparities regarding disease support groups, 
especially for diseases with lower prevalence rates such as Huntington disease and Parkinson 
disease. The addition of more patient support groups in this region may have many benefits, 
including increased awareness and education, and more patient and caretaker empowerment. 
These benefits may in turn impact the overall health of a region that historically has had issues 
with healthcare access and availability. I recommend that more research into this potential 
disparity is performed to investigate it further.  
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1.0 INTRODUCTION AND IMPORTANCE OF DISEASES 
 The purpose of this essay is to examine patient and caregiver support groups for those 
affected by adult-onset neurological genetic disorders. The focus is on four specific diseases that 
(1) display a plethora of neurological symptoms, (2) typically affect middle to advanced age 
adults, and (3) carries a significant risk of familial heritability. These four diseases include 
Huntington disease (HD), Amyotrophic lateral sclerosis (ALS), Alzheimer disease (AD), and 
Parkinson disease (PD). These four disorders were chosen due to their prevalence in the United 
States, the individual epidemiology of each disorder, the similar progression and treatment 
options, and the connection between these diseases and support groups.  
My research focused on the central and northern states of the Appalachian region of the 
continental United States: West Virginia, Pennsylvania, Ohio, Maryland, Kentucky, and 
Virginia. This specific area was chosen to assess the potential dichotomy of health care access 
and support that exists between economically privileged and distressed areas of the region. An 
evaluation of location of support groups, and the economic status of the area in which they are 
located was conducted. A review of the benefits of support groups for patients and caregivers 
was performed.  
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1.1 DISEASE PREVALENCE AND PUBLIC HEALTH SIGNIFICANCE  
 One of the many reasons that the four specific neurological diseases discussed in this 
essay were chosen had to do with the relatively low prevalence of some of the disorders. Support 
groups are a vital resource for patients and caretakers, and these groups tend to be fewer in 
number and lower in availability for diseases that have a lower prevalence rate (Molster, et al., 
2016). This creates a disparity for those afflicted with or by these disorders. 
In the U.S., the prevalence rates for Huntington disease, Amyotrophic lateral sclerosis, 
and Parkinson disease are 1 per 10,000 people, 2 per 100,000 people, and 13 per 100,000 people 
respectively (Pringsheim, et al., 2012; Ferraiuolo, et al., 2011; Samii, et al., 2004). These rates 
are quite low when compared to Alzheimer disease, that affects one in nine people over the age 
of 65, and over 5 million people in the United States have. Alzheimer disease is also the 6th 
leading cause of death in the United States (Gaugler, et al., 2015). This disease comparison 
makes for interesting results when investigating the support groups for each given disease, and 
further highlights the dichotomy that exists between diseases with higher prevalence and those 
with low prevalence.  
The lack of support for disorders of lower prevalence is of major public health 
significance because support groups are integral to patients’ and caretakers’ well being, and are 
an important community and healthcare resource. These groups provide vital disease information 
to patients and their families (Locock & Brown, 2010). The problems that are associated with the 
lack of patient support are magnified in areas of the United States with higher poverty rates and 
more geographically isolated areas, like the Appalachian region. Other issues, such as healthcare 
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burden, also contribute to the need for patient support groups in this region. The Appalachian 
region has a physician and provider shortage, as well as limited hospital bed space available 
(Lane, et al., 2012). 
In addition to the healthcare burden and lack of access, a general lack of education, 
combined with the low health literacy rate throughout the United States contributes to the 
healthcare environment of Appalachia (Kutner, et al., 2006). The healthcare challenges of this 
region are unique and thus an assessment of the impact of the four neurological diseases on the 
general well-being of the region is critical to develop possible interventions, such as increasing 
the number of support groups, to mitigate some of the health care burden of disease. However, it 
also makes this region one that is unique and interesting to research.  
1.2 SIGNIFICANCE OF GENETIC COUNSELING AND GENETIC TESTING 
Since all the neurological disorders discussed in the essay can be inherited, it is important 
to touch on the aspects of genetic counseling and testing. Genetic testing is a complicated and 
highly personal decision, and not every patient or family may be interested in pursuing available 
genetic testing. However, in order for a patient or family to make an informed decision regarding 
genetic testing, it is advised that they seek the advice of a certified genetic counselor, if they 
choose to receive information about genetic testing 
Genetic counselors are health professionals with training in counseling and genetics who 
work as part of a healthcare team including physicians, nurses, and other healthcare providers 
(NSGC, 2016). Genetic counselors provide information and support to families and individuals 
with established genetic disorders and to those who are at risk for developing these disorders. 
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They identify risk within families, investigate this risk, interpret information and educate patients 
and their families about the disorder, risks, and potential heritability (NSGC, 2016). They also 
review options with the individual or family, which may include genetic testing.  
1.3 ECONOMIC BURDEN OF DISEASES 
 Although HD, PD, and ALS diseases have a low prevalence rate, and are rare in the 
general population, their economic burden is substantial. Most of this burden is due to outpatient 
costs and most of these costs are borne by the affected individual and his/her family. These costs 
vary greatly among patients depending on disease stage, symptoms, available resources, and 
insurance coverage. A large encumbrance is placed on society as well.  
The per patient cost of Huntington disease may be large, mostly due to outpatient 
services such as nursing homes. Because more late-stage HD patients utilize these services, the 
cost per patient increases with disease progression. Divino and colleagues (2013) assessed the 
individual patient costs by comparing individuals using the Thomson Reuters’ MarketScan 
commercial insurance and Medicaid databases from the years 2002 through 2009. Among a 
sample size of 1,272 HD patients from across the U.S., the annual per patient costs of HD for 
commercial insurance users ranged from $4,947 to $22,582, and the Medicaid patient costs 
ranged from $3,257 to $37,495, and these are the annual per patient costs. The larger range for 
Medicaid patients was attributed to their usage of nursing facilities; close to 75% of late stage 
HD patients used nursing homes and facilities, while over 50% of commercial patients used 
these services. It is worth noting, however, that this sample of Medicaid HD patients was 
classified as late stage while the sample size who used commercial insurance contained a more 
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event distribution of disease stage.  Because Medicaid is a government-supported program, these 
costs also take a toll on society (Divino, et al., 2013).  
Based on the comprehensive work of Larkindale and colleagues (2014), the costs for 
ALS are also very high, approximately $31,121 per patient annually. This cost includes medical, 
non-medical, and indirect costs, with most of the direct medical costs related to outpatient 
services and treatments. These costs were determined by using information from claims 
databases for those using private insurance plans and those using Medicare across the U.S., 
totaling to 1,528 ALS patients.  Nonmedical costs include modification of homes, vehicles, food 
and travel, and caretakers. Indirect costs were defined as loss of family income determined by 
Cost of Illness surveys distributed to 600 households registered with Muscular Dystrophy 
Association (MDA). Among this sample, 124 individuals reported being an ALS patient or 
having a family member afflicted with ALS. The nonmedical costs came to a total of $17,889. In 
assessing all of these costs and the prevalence of ALS, the annual societal cost of this disease in 
the United States was found to be between $256 and $433 million  (Larkindale, et al., 2014).  
Parkinson disease also results in high medical and non-medical costs. The national 
economic burden of PD in 2010 was estimated to be $14.4 billion, about $22,800 per patient. 
This included medical, non-medical, and indirect costs. The prevalence rates of PD are likely 
underestimated, thus true costs may also be underestimated. Medical and non-medical costs also 
increase as severity of symptoms increase (Kowal, et al., 2013).  
Alzheimer’s disease far and away trumps the costs of the other three disorders, due to the 
higher prevalence of this disease. The average annual per patient cost for Medicare beneficiaries 
for health care and long-term services totals to $47,752, a figure that does not include indirect 
costs such as loss of income and that is based off of findings from the 2008 Medicare 
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Beneficiary Survey Report and Medicare Part B claims for those with dementia (Hebert, et al., 
2013). This survey includes Medicare beneficiaries living in communities and in nursing homes 
or residential care facilities.  For 2015, it has been estimated that the total costs of health care, 
long-term care, and hospice for individuals with Alzheimer’s and other dementias in the U.S. 
was estimated to be $226 billion; government health programs such as Medicare and Medicaid 
covered $153 billion, or 68% of costs (Gaugler, et al., 2015). These are astronomical numbers, 
and a huge burden placed on society. This number is especially concerning, given that the 
number of patients with AD is expected to increase significantly, from 5.3 million to 13.8 
million, within the coming decades (Hebert, et al., 2013; Gaugler, et al., 2015).  
In summary, the substantial economic burden of these disorders demonstrates the need 
for further research, increased diagnosis, and more comprehensive treatments for patients. It also 
validates the public health significance and importance of neurological diseases, and why 
integral support services are needed for these patients, although some of these disorders are 
considered to be low prevalence. Although these financial estimates are alarming, the emotional, 
mental, and physical burdens faced by patients, families, and caretakers are just as meaningful, 
and perhaps even more worrisome.  
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2.0 DISEASE OVERVIEW AND GENETICS 
2.1 HUNTINGTON DISEASE (HD) 
2.1.1 HD OVERVIEW 
 Huntington disease is a progressive, neurodegenerative disease that primarily affects the 
basal ganglia, a group of nerve cells at the base of the human brain. The basal ganglia are 
involved with different aspects of motor control, cognitive abilities, and sensory pathways. 
Disruption of these functions by an altered version of the huntingtin protein ultimately leads to 
the cellular death of the basal ganglia, producing the pathology seen with HD. Patients typically 
live 15 to 20 years after the onset of symptoms (Landles & Bates, 2004). 
The symptoms of Huntington disease lie on a wide and varied spectrum, leading to 
different symptom manifestation between patients that are dependent on age of onset (typically 
affecting middle aged adults), general health, genetics, and the individual neurobiology of the 
affected patient. There are many changes that can be seen in an affected patient, and they are 
classified into various groups. Movement disorders may include involuntary movements, as well 
as impairments in existing voluntary movements. These may involve: involuntary jerking or 
writhing (chorea), muscle rigidity or contracture (dystonia), slow or abnormal eye movements, 
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impaired gait, balance, and posture, and difficulty swallowing or physically producing speech 
(Landles & Bates, 2004).  
There are also multiple cognitive symptoms that may be seen in patients with HD, such 
as: difficulty with focus and organization, lack of mental flexibility (preservation), difficulties 
with impulse control, lack of behavioral awareness, disruptions of thought, and difficulty 
processing new information (Bates et al., 2015).  There are also psychiatric disorders that can be 
attributed to HD. The most common disorder associated with HD is depression (Labbadia, 
Morimoto, 2013). This is not considered to be a mental reaction to a diagnosis of HD, but rather 
it is a physical manifestation caused by injury to the brain and disruptions of neurological 
function (Bates, et al., 2015). Other common psychiatric disorders that may occur in tandem with 
HD are obsessive-compulsive disorder and schizophrenia-like psychosis (Bates, et al., 2015).  
Collectively all types of these symptoms often start prior to when a formal diagnosis is received 










 Figure 1: Onset of Symptom Type throughout Progression of Huntington Disease 
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There are currently no treatments available to slow the progression of HD, but drug 
therapies do exist to treat the movement and psychiatric disorders associated with the disease 
(Labbadia, Morimoto, 2013). Other treatments, such as speech, physical, and occupational 
therapies may help the patient to handle the symptoms (Bates, et al., 2015).   Psychotherapy may 
also help with psychiatric issues, but also with coping mechanisms, and managing expectations 
during the progression of disease (HDSA, 2016). 
It has been estimated that there are roughly 30,000 cases of HD in the United States, 1 
per 10,000 people, but there have been conflicting reports based on the ethnic groups and 
counties used in sample sizes (Pringsheim, et al., 2012; Rawlins, et al., 2016; Landles & Bates, 
2004).  However, due to a lack of incidence and prevalence studies available, it has been difficult 
to assess a period prevalence of this disease in the United States (HDSA, 2016). A fairly recent 
meta-analysis shows period prevalence of HD as 5.70 per 100,000 people starting in 1985 and 
ending in 2012 (Pringsheim, et al., 2012). However, this analysis included study populations 
from North America, Europe, and Australia, and of this analysis, only one prevalence study was 
from a United States population, from 1990 (Pringsheim, et al., 2012).  
A more recent study has reported that prevalence rates vary widely among different 
populations, and shows that the prevalence in Asian populations decreasing while the prevalence 
in the Western Europe, North America, and Australia has been increasing over the last 50 years 
(Rawlins, et al., 2016). Because HD is so varied around the world, studies could be affected 
depending on what populations, including discreet populations, are in the cohort of a given 
study. The rise of HD in primarily Caucasian populations could be due to a number of reasons 
including better diagnostic knowledge, the wider availability of genetic testing, and potentially 
increased mutation rates (Rawlins, et al., 2016).  
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2.1.2 HD GENETIC ATTRIBUTES 
 The mutated HTT gene, located on 4p16.3, is known to be the cause of HD. The normal 
function of the HTT gene is to encode for the huntingtin protein, which appears to play a role in 
the functionality of neurons and is essential for normal fetal development, although the exact role 
of this protein is not yet known (Landles & Bates, 2004).  While huntingtin is found in many cell 
types in the body, the highest level of this protein is found in the brain (Landles & Bates, 2004).   
Huntingtin is involved in several cellular processes including chemical signaling, cellular 
transport, protein binding, and protecting the cell from apoptosis (Warby, et al., 2014). A 
particular region of the gene contains a polyglutamine tract (CAG repeat region). Under normal 
circumstances, the HTT gene has 10-35 CAG repeats (Warby, et al., 2014).  
 The CAG segments contributes to the development of HD when a mutation occurs that 
causes these segments to expand. When they expand, a longer version of the huntingtin protein is 
made. This elongated protein is cleaved into smaller segments during the process of post-
translational modification (Labbadia & Morimoto, 2013).  When parts of this protein is in 
overabundance in a particular location of the brain, the polar nature of glutamine allows for 
protein binding (Labbadia & Morimoto, 2013). Thus, these segments will ultimately bind 
together in a clumped, aggregate form rather than fold into normal, functioning proteins 
(Labbadia & Morimoto, 2013).  As more of these protein aggregates form, they coalesce into 
bigger forms called inclusion bodies, which disrupt normal neuronal function (Rubinsztein & 
Carmichael, 2003).  
 These aggregates can collect on the axons and dendrites of neurons, which leads to a 
mechanical breakdown of neurotransmitter movement (Labbadia & Morimoto, 2013).  Due to 
this breakdown, neuronal signaling degenerates, producing the clinical symptoms of HD. This 
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mutated huntingtin protein also can disrupt neuronal function outside of the movement of 
neurotransmitters (Rubinsztein, Carmichael, 2003). The protein aggregates can disrupt the 
functions of chaperone proteins, caspases, cellular energy production, and the expression of other 
genes; this can ultimately lead to the cellular death, which is seen in the pathology of HD 
patients (Rubinsztein, Carmichael, 2003).  
  The CAG repeats in HD patients can be between 36 and 120 repeats (Warby, et al., 
2014). Those with 36-39 repeats may or may not develop the disease, whereas people with 40 or 
more repeats nearly always do (Warby, et al., 2014). Individuals at the higher end of the 
“normal” CAG repeat spectrum (27-35) typically do not develop HD, but are at risk for having 
children who may progress to the disorder, because as the HTT gene passes from one generation 
to the next, the size of the CAG segment often increases (Warby, et al., 2014). HD is inherited in 
an autosomal dominant fashion, which means that only one copy of the allele needs to be present 
to produce disease (Rubinsztein, Carmichael, 2003). Thus, a patient has a 50% chance of 
inheriting the altered HTT allele from an affected parent. It is rare that a patient will develop HD 
without inheriting the altered version of the HTT gene (Warby, et al., 2014). 
2.2 AMYOTROPHIC LATERAL SCLEROSIS 
2.2.1 ALS OVERVIEW 
Amyotrophic lateral sclerosis (ALS), commonly known as Lou Gehrig’s disease, is a 
neurodegenerative disease that attacks neurons, specifically those that are responsible for 
voluntary motor movements (NINDS, 2013).  It is also a rapidly progressive and often deadly 
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disease (NINDS, 2013). This disease targets the motor neurons in the upper and lower parts of 
the motor cortex of the brain, as well as the neurons in the brain stem and spinal cord 
(Ferraiuolo, et al., 2011). Prior research has indicated that ALS was simply a motor neuron 
disease, affecting only physical voluntary movements (Ferrari, et al., 2011). However, in the last 
two decades, research has indicated that about 20 percent of ALS patients are also affected by 
frontotemporal dementia (FTD) (Ferrari, et al., 2011).  This combination of ALS and FTD can 
lead to changes in personality, behavior, and communication skills (Ferrari, et al., 2011). There is 
also a rare form of ALS known as ALS-parkinsonism-dementia complex (ALS-PDC) (Waring, 
et al., 2004). Along with the signs and symptoms of ALS, there are additional movement 
abnormalities present, such as slow movements, stiffness, and tremors, as well as a progressive 
loss of intellectual function (ALSA, 2016).  
The physical symptoms of ALS include: difficulty walking, tripping, weakness in 
extremities, speech slurring, difficulty swallowing, muscle cramps, twitching in arms, shoulders, 
and tongue, and difficulty holding up the head or maintaining good posture (NINDS, 2013). The 
disease usually begins in the auxiliary limbs, and then spreads to other areas of the body (Ferrari, 
et al., 2011).   In addition to difficulties in speaking and swallowing, the neurons that are also 
responsible for breathing are eventually affected (NINDS, 2013).  The disease typically begins 
between the ages of 55 and 60 (Ferraluolo, et al., 2011). Disease progression varies widely 
among those affected, but most patients diagnosed with the disease will die from respiratory 
failure 3-5 years after the onset of symptoms (Ferrari, et al., 2011).  
There are some risk factors for ALS, stemming from environmental triggers. Survey 
module analysis performed with 1,647 participants from the National ALS registry (Mehta, et al., 
2014) have also indicated that smoking and workplace exposure to lead and a history of military 
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service may correlate with ALS development (Mehta, et al., 2014; NINDS, 2013). However, it is 
important to note that this is a correlation and there are no conclusions that smoking, lead 
exposure, or military service triggers ALS (Mehta, et al., 2014).It is not truly known why the 
latter is a trigger, but it has been postulated that exposure to certain metals or chemicals, 
traumatic injury, exertion, and viral infections could have something to do with this relationship 
(Mehta, et al., 2014). 
There is no cure for ALS, thus treatment focuses on slowing the progression of the 
disease, and prevention of complications (Ferrari, et al., 2011).  In 1995, the Food and Drug 
Administration (FDA) approved the only drug shown to help with slowing disease progression, 
riluzole (Rilutek) (ALSA, 2016). This drug reduces the release of glutamate in the brain, a 
chemical messenger that appears to be significantly higher in ALS patients (NINDS, 2013). In 
clinical trials, this drug has been shown to prolong life expectancy, and extends the time before 
respiratory distress becomes a major issue for patients (NINDS, 2013). Combination drug 
therapies may be used for symptoms specific to the patient, in order to make him or her as 
comfortable as possible (NINDS, 2013). There are also many therapies that can help improve the 
quality of life of ALS patients. These include: breathing care, physical, occupational, and speech 
therapies, dietary support, and psychological support (NINDS, 2013).  
The exact prevalence of ALS is hard to determine, given that historical records have not 
been kept, and that ALS is not a reportable disease on a national level (Mehta, et al., 2014).  
Recent reports have estimated that there are more than 12,000 people living with ALS in the 
United States, with approximately 6,000 new diagnoses each year (ALSA, 2016). The incidence 
rate of the disease is 2 per 100,000 people (Ferraiuolo, et al., 2011). Most of these cases are 
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considered to be sporadic (90-95%), with only 5 to 10% of ALS patients having an inherited 
form of the disease (Ferraiuolo, et al., 2011). 
In 2009, the federal Agency for Toxic Substances and Disease Registry (ATSDR) began 
the first registry for ALS patients (Mehta, et al., 2014). This registry helps to provide information 
about prevalence and incidence rates, and environmental triggers that may have a role in causing 
ALS (Mehta, et al., 2014).  This has been a successful public health measure. In little more than 
a year (October 2010-December 2011), over 12,000 people in the United States with ALS joined 
the registry (Mehta, et al., 2014). The registry was also able to provide valuable information on 
risk related to sex, ethnic background, health history, and occupation. Hopefully this will 
continue to be utilized by patients and physicians to gain more knowledge about ALS (Mehta, et 
al., 2014).  
2.2.2 ALS GENETIC ATTRIBUTES 
 Although environmental triggers play an important role of disease development, there are 
several genes that are related to, and may be responsible for, ALS (DeJesus-Hernandez, et al., 
2011). One of the major genes that account for familial cases of ALS is the chromosome 9 open 
reading frame 72 gene (C9orf72) (DeJesus-Hernandez, et al., 2011). This gene is located on the 
short arm of chromosome 9p21.2 (DeJesus-Hernandez, et al., 2011). Under normal conditions, 
this gene provides instructions for making a protein that is in the cerebral cortex, and in motor 
neurons (DeJesus-Hernandez, et al., 2011). This protein also is believed to have a heavy impact 
on the functionality of RNA. C9orf72 also contains a hexonucleotide repeat segment composed 
of four guanines and two cytosines (GGGGCC) (DeJesus-Hernandez, et al., 2011).  Studies 
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suggest that 30 or less of these repeats will result in normal gene function (Todd & Petrucelli, 
2016). 
It is unclear by what mechanism the disease is caused (DeJesus-Hernandez, et al., 2011). 
The two primary theories are that either the expansion reduces C9orf72 function or leads to the 
production of an abnormally functioning protein that both disrupts RNA function and protein 
production in the cell, contributing to the growth of protein aggregates (DeJesus-Hernandez, et 
al., 2011; Todd & Petrucelli, 2016).  Overall disruption to the C9orf72 protein function can lead 
to premature motor neuron death, which contributes to the pathology of ALS (Todd & Petrucelli, 
2016). 
Another gene that contributes to ALS cases is the superoxide dismutase 1, soluble 
(SOD1) gene. This gene is located on 21p22.11 (Andersen & Al-Chalabi, 2011). The normal 
function of the SOD1 gene is to make an enzyme called superoxide dismutase, which attaches to 
copper and zinc molecules in order to breakdown toxic superoxide radicals (Andersen & Al-
Chalabi, 2011). These radicals are the result of normal cellular processes, and must be broken 
down to avoid damage in the body (Andersen & Al-Chalabi, 2011). Most of the mutations that 
are associated with the disease are missense mutations. which can occur when one amino acid is 
substituted for another (Bertolin et al, 2014). It is not clear why motor neurons are affected by 
SOD1 mutations, but researchers have proposed that this could be due to an increase in 
superoxide and other toxic radicals, increased levels of apoptosis, and aggregates of misfolded 
superoxide dismutase (Andersen & Al-Chalabi, 2011).  
The FUS RNA binding protein (FUS) has also been shown to have many mutations that 
can lead to ALS (Ferraiuolo, et al., 2011). The FUS gene (located on 16p11.2) is normally 
responsible for making a protein that helps to regulate transcription, the processing of messenger 
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RNA (mRNA) via alternative splicing, and repairing mistakes in DNA (Ferraiuolo, et al., 2011). 
Most of these mutations are also missense and primarily affect the parts of the protein involved 
in DNA binding and mRNA processing, particularly hindering mRNA transport out of the cells, 
which causes mRNA to become trapped in the cells and form aggregates (Andersen & Al-
Chalabi, 2011). Patients who have ALS caused by FUS mutations tend to have a shorter life 
expectancy and the onset of the disease occurs at a younger age (Bertolin, et al., 2014). 
The TAR DNA binding protein gene (TARDBP), is responsible for making a protein 
called transactive response DNA binding protein 43 kDa (TDP-43) (Borroni, et al., 2010). It is 
located on 1p36.22 (Borroni, et al., 2010). This protein has several functions relating to protein 
production such as, regulating transcription, RNA binding, and mRNA processing via alternative 
splicing (Borroni, et al., 2010). This protein is particularly active during fetal development and it 
influences production of proteins involved in the nervous system and organ development 
(Borroni, et al., 2010).  Many missense mutations of the TARDBP gene have been found to cause 
ALS (Andersen & Al-Chalabi, 2011).  The majority of these mutations affect mRNA processing, 
which disrupts the production of other proteins and leads to mRNA aggregates within the cell 
(Borroni, et al., 2010).  
The pattern of inheritance associated with ALS is dependent on what gene is responsible 
for causing the disease. Most mutations are inherited in an autosomal dominant fashion, in which 
a mutation in one copy of the gene is enough to cause the disease (Ferraiuolo, et al., 2011).  
However, there is also reduced penetrance in many of these mutations, meaning that, a person 
can inherit a disease causing mutation, but never progress to illness (Andersen & Al-Chalabi, 
2011).  Although it is not as common, ALS can also be inherited in an autosomal recessive 
pattern, in which a person would need two copies of the mutated allele, one from each parent, in 
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order to progress to a diseased state. In this case, the parents do not show symptoms of the 
disease, so the affected patient’s diagnosis of ALS is typically classified as sporadic (Conforti, et 
al., 2008). In very rare cases, it is also possible for ALS to be inherited in an X-linked dominant 
pattern, in which females would only need to inherit a mutation on one of their two X 
chromosomes to be affected, and males would be affected if they inherit a mutation on their one 
X chromosome, which they always receive from their mother (Deng, et al., 2011).  
2.3 ALZHEIMER DISEASE (AD) 
2.3.1 AD OVERVIEW 
 Alzheimer disease is a progressive, neurodegenerative disorder that affects memory and 
cognitive abilities. It is the most common cause of dementia among older adults, as well as the 
sixth leading cause of death in the United States (Cummings, 2004). With AD, the patient’s 
neurons progressively lose function and die off (Cummings, 2004). This occurs in multiple parts 
of the brain, including the cerebral cortex, temporal and parietal lobes, frontal cortex, cingulate 
gyrus, and in parts of the brainstem (Mattson, 2004).  Survival times can range anywhere from 1 
to 25 years after symptom onset, with most patients surviving an average of 8 to 10 years (NIA, 
2015; Mattson, 2004). The first symptoms that patients usually experience are loss of memory 
and mild confusion (NIA, 2015).  These start when the patient experiences short term memory 
loss, and as the disease progresses, the memory problems get steadily worse, leading to the 
inability to identify objects, express thoughts, and remember the names or lives of friends, family 
members, or themselves (Cummings, 2004). 
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 Thought processes and reasoning abilities can become impaired, especially those 
involving more complex concepts such as numbers (Gaugler, et al., 2015).  The ability to 
multitask also declines, and both of these aspects can usually manifest themselves in a patient’s 
finances, which may ultimately further decrease their quality of life (Gaugler, et al., 2015). 
Judgment and decision making are also affected, which could lead to the patient putting 
themselves or others in dangerous situations (NIA, 2015). Planning and performing familiar 
tasks are also abilities that may be adversely affected, affecting the patient’s daily routine greatly 
(NIA, 2015). There are also psychiatric issues that can occur in conjunction with AD such as 
changes in personality and behavior. These include: depression, apathy, mood swings, 
distrustfulness, irritability and aggressiveness, changes in sleeping habits, loss of inhibitions, 
wandering, and delusions (NIA, 2015; Cummings, 2004).  As AD progresses into later stages, 
the changes in the brain can often manifest into physical symptoms. These include swallowing, 
balance, and bowel and bladder control (Gaugler, et al., 2015). 
 There are many risk factors that pertain to AD, with age being the most significant factor 
(Harmen, 2006). AD usually affects patients 65 years of age and older, although some people 
with rare genetic mutations can begin to see symptoms as young as 30 (Harmen, 2006). Family 
history and genetics plays an important role in the development of AD, with risk especially 
increasing if a person has a first degree relative (a member of the immediate family) who has the 
disease (Gaugler, et al., 2015). Having Down syndrome is also a major risk factor for AD 
development, with patients developing symptoms of AD 10 to 20 years earlier than the general 
population (Lott & Head, 2005).  This is believed to occur due to a gene inherited on 
chromosome 21,the extra chromosome that causes Down syndrome (Lott & Head, 2005).  
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 Other risk factors for AD include a patient’s health history, particularly if that person has 
had a past head trauma, both a single incident as well as repetitive head injuries (Sivanandam & 
Thakur, 2012).  This factor is believed to increase the risk of amyloid protein deposition in the 
brain (Sivanandam & Thakur, 2012).  Certain aspects of heart health can also contribute to the 
development of AD (Cummings, 2004). Some of these factors include: lack of exercise, obesity, 
smoking, high blood pressure, high cholesterol levels, poor diet, and poorly controlled type 2 
diabetes (Mattson, 2004). 
` While there is no cure for AD, there are drugs available to help with the management of 
cognitive changes. Cholinesterase inhibitors work to help replenish depleted acetylcholine, a 
neurotransmitter that boosts cellular communication (Cummings, 2004). This inhibitor can also 
help some of the psychiatric symptoms of AD, such as agitation or depression (Cummings, 
2004). Another pharmaceutical, memantine (Namenda) can improve cellular communication and 
this helps to slow the progression of the cognitive symptoms, particularly in patients with 
moderate to severe AD (Cummings, 2004; NIA, 2015).  Other psychiatric drugs, such as anti-
depressants or anti-anxiety medications, can be used in combination with those listed above to 
help alleviate some symptoms and make the experience easier on the patient, but only when 
behavioral healthcare measures have been taken first (Cummings, 2004).   
 Arguably, one of the most important parts of the treatment plan for AD is creating a safe 
environment for the patient to live, with support from both a medical team and loved ones 
(Mattson, 2004). Exercise and nutrition are also important aspects of care; these not only work to 
improve physical health, but can also help to alleviate some psychiatric symptoms such as mood 
changes and depression (Cummings, 2004). These treatment plans are also helpful in allowing 
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the patient and the caregivers to establish a regular daily routine (Cummings, 2004; Gaugler, et 
al., 2015).  
 In 2015, approximately 5.3 million Americans were living with AD; 5.1 million people 
out of this number are 65 years and older (Gaugler, et al., 2015). Approximately 500,000 people 
in the United States are diagnosed with AD each year (Gaugler, et al., 2015). From these 
numbers it is quite easy to tell how risk of having AD increases with age. This is especially a 
concern with the aging population of the United States. People are living longer, but they are also 
at risk for more diseases as they age (Riedel, et al. 2015). Due to these increased prevalence and 
incidence rates, the number of Alzheimer’s patients in the United States is expected to double by 
2025 (Gaugler, et al., 2015).  
Women have also been found to be most at risk, with an estimated two-thirds of current 
American AD patients being women (Riedel, et al. 2015). There are also racial and ethnic 
differences in AD patients. African Americans and Hispanics are twice as likely and one and a 
half more times as likely to develop AD when compared to non-Hispanic whites, respectively 
(Riedel, et al. 2015). Both the sex and racial differences can be attributed to a number of factors. 
Age is the most important factor for the differences between the sexes because women tend to 
live longer than men, thus having a higher risk of developing AD (Ghebremedhin, et al., 2001). 
For the differences by both sex and race, variations in lifestyle, health, and socioeconomic status 
can be related to risk of AD (Ghebremedhin, et al., 2001; Riedel, et al. 2015).  
 Due to the increased surveillance for and incidence of AD, compared to other 
neurological disorders, researchers have the opportunity to compare the number of AD patients 
by state in the United States, and make future predictions using these numbers (Gaugler, et al., 
2015). The states within the central Appalachian region of the United States have different rates 
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or projected increases of AD (Gaugler, et al., 2015). This is important given the focus on support 
groups for this essay. The figure below shows projected increases of Alzheimer’s disease 
between 2015 and 2025. It is important to note that every state in the United States is increasing 
by some amount; none are staying the same or decreasing (Gaugler, et al., 2015).  
2.3.2 AD GENETIC ATTRIBUTES 
 Although AD is considered to be a multi-factorial disease, there are genetic attributes that 
play a role in disease pathology, especially in the cases of early onset AD (Riedel et al., 2015). 
These genetic attributes are inherited in an autosomal dominant fashion in the cases of early 
onset AD, whereas the cases of late onset AD have inheritance patterns that are difficult to 
determine (Mattson, 2004). There are three genes that contribute to early onset AD. There are 
potentially many genes that could have an effect on the development of late onset AD, and these 
are usually population specific (Bird, 2008). One specific gene related to late onset AD that has 
been extensively studied in relation to late onset AD is the apolipoprotein E gene (APOE). 
 Under normal conditions, APOE provides instructions for making apolipoprotein E 
(Riedel et al., 2015).  This protein produces lipoproteins by combining with fat molecules 
(lipids). Lipoproteins package and carry fats throughout the bloodstream, which helps the body 
to maintain a normal and healthy amount of cholesterol in the blood (Riedel et al., 2015).  There 
are three alleles known in the human population: e2, e3, and e4, with e3 being the most common, 
found in more than half of the world’s population (Riedel et al., 2015). The APOE gene is 
located at 19p13.2  (Riedel et al., 2015).  
 The e4 allele of the APOE gene has been shown to increase a person’s chances of 
developing AD, with the amount of risk increasing if two e4 alleles are inherited (Bird, 2008). It 
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is not known exactly how the e4 allele is related to AD, but there have been significant 
associations between the APOE e4 genotype and the presence of neurofibrillary tangles and 
amyloid plaques characteristic of AD (Bird, 2008). Neurofibrillary tangles are aggregates of tau 
protein that has been hyperphosphorylated and amyloid plaques are aggregates of misfolded 
proteins (Mattson, 2004).  These both work to physically disrupt neuronal function, eventually 
leading to neuron death and contributing to the pathobiology of AD (Mattson, 2004). 
 The amyloid beta precursor protein gene (APP) is located on chromosome 21q21.3 (Bird, 
2008). This gene provides instructions to make the amyloid precursor protein, a protein found 
throughout the body (Bird, 2008). The normal function of this protein is still uncertain, although 
some studies have suggested that it may aid in the movement of neurons (Rogaeva, et al., 2007). 
This protein is also cut into smaller fragments by enzymes (Mattson, 2008). Two of these 
fragments, soluble amyloid precursor protein (sAPP) and amyloid beta (β) play an important role 
in the functions of neurons (Mattson, 2008). sAPP aids in the formation of nerve cells and 
protein inhibition, while amyloid beta aids in the adaptability of neurons (Mattson, 2008). APP 
contains many mutations that are related to early-onset AD, although these mutations are 
responsible for a small number of cases (Bird, 2008). The mutations cause an abnormal amount 
of amyloid beta protein to be created or can cause longer proteins that are more likely to form 
aggregates (Harmen, 2006). The increased amount and altered version of amyloid beta can 
accumulate and stick together, forming the amyloid plaques that contribute to neuron death in 
AD (Sivanandam & Thakur, 2012).  Since APP is also on chromosome 21, those with Down 
syndrome inherit an extra copy of this gene, increasing the production of amyloid beta protein, as 
well as risk of AD development (Bird, 2008). 
 23 
 Presenilin 1 (PS1) is a gene responsible for making the presenilin 1 protein. This protein 
is part of a larger complex called gamma- (γ-) secretase (Gómez-Isla, et al. 1999).  Presenilin 1 
carries out the major function of the complex, which is to cleave other proteins into fragments 
(Gómez-Isla, et al. 1999).  This is the protein complex responsible for cutting the amyloid 
precursor protein into sAPP and amyloid beta protein (Mattson, 2008). This gene is located at 
14q24.3. Many of the mutations related to this gene that can be related to early onset AD 
(Gómez-Isla, et al. 1999).   The defective presenilin 1 protein disrupts the function of the gamma 
secretase complex, leading to processing errors in APP that aids in producing the amyloid 
plaques seen in AD (Gómez-Isla, et al. 1999).  
 The presinilin 2 gene (PS2) makes the presenilin 2 protein. This gene is located at 
1q42.13. This protein works to help process chemical signaling proteins (Gómez-Isla, et al. 
1999). These chemical signals activate genes that are important for cellular growth and 
maturation (Gómez-Isla, et al. 1999). Presinilin 2 also processes amyloid precursor protein 
(Gómez-Isla, et al. 1999). Mutations in this gene lead to overproduction of amyloid beta protein, 
increasing the formation of protein aggregates (Gómez-Isla, et al. 1999). 
2.4 PARKINSON DISEASE (PD) 
2.4.1 PD OVERVIEW 
 Parkinson disease is a progressive disorder that affects the nervous system, especially an 
area in the middle of the brain called the substantia nigra that controls movement (Obeso, et al., 
2008).  The disease begins gradually, usually on one side of the body, but over time will affect 
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all movements (Samii, et al., 2004).  The disease can progress to include cognitive and 
psychiatric symptoms (Samii, et al., 2004).  PD can be either late or early onset, but the majority 
of patients develop the disorder after the age of 50 (Samii, et al., 2004).  
 The symptoms of PD can vary from person to person, and many of the early signs can be 
mild causing them to go unnoticed during clinical evaluation (Samii, et al., 2004). The typical 
first sign of PD is a tremor, usually beginning in a specific limb, when the body is at a complete 
rest (Nuytemans, et al., 2010). Slowed movement, as well as muscle rigidity, begins to occur as 
the disease progresses (Obeso, et al., 2008). Other symptoms may include impairments in 
posture and balance, loss of automatic movements, speech changes and motor changes. Some 
individuals may experience psychiatric symptoms such as depression and hallucinations (Samii, 
et al., 2004).  Those affected with PD also have an increased risk of developing dementia (Samii, 
et al., 2004).  
PD symptoms begin when the neurons in the neurons in the substania nigra begin to die 
due to a lack of dopamine, an essential chemical messenger that controls communication 
between the brain and the muscle cells of the body (Obeso, et al., 2008).  Lewy Bodies, which 
are protein aggregates that coalesce around neurons, are also a hallmark of Parkinson disease. 
They can be made up of a variety of proteins, and their role in PD is not fully understood 
(Kalinderi, et al., 2016). PD cannot be cured, but treatment is available to alleviate some of the 
symptoms (Samii, et al., 2004). The majority of medications used for the treatment of PD act to 
affect the dopamine insufficiency. (Samii, et al., 2004).  These medications work by replacing 
dopamine, replicating the effects of dopamine, or by preventing the breakdown of already 
existing dopamine (Samii, et al., 2004).  There are also medications available to help control 
involuntary movements and tremors (Samii, et al., 2004).  In addition to drug therapy, there is 
 25 
also an operation that PD patients can have called deep brain stimulation, which involves the 
implantation of electrodes in a specific part of the brain (Samii, et al., 2004). These electrodes 
send electrical pulses to the brain to control PD symptoms (Samii, et al., 2004). 
 PD occurs in 13 people per 100,000 (Samii, et al., 2004). The prevalence of PD is 
estimated to be one to two percent of the population older than 60, worldwide (Nuytemans, et al., 
2010).  While this disease may not be fatal, these numbers and the effects that PD has on a 
person’s everyday life signal the need for more research, as well as more medical and social 
support for patients. (Samii, et al., 2004). 
2.4.2 PD GENETIC ATTRIBUTES 
 Although PD is considered to be a multi-factorial disease, there are several genes that can 
play a significant role in the pathology of the disorder. Of the cases of PD that are considered to 
be inherited, mutations in one of five known genes may have caused the disorder (Klein & 
Westenberger, 2012).  However, there are two other genes that do not directly cause PD, but may 
modify the risk of PD development in some families (Kalinderi, et al., 2016). While the basic, 
normal functions of these genes are readily known, the mechanisms by which they cause PD 
remain inconclusive (Klein & Westenberger, 2012). The five genes that are believed to cause PD 
are all within the PARK family of genes (Klein & Westenberger, 2012).  
The leucine-rich repeat kinase 2 gene (LRRK2) is responsible for producing the protein 
dardarin (Hardy, et al., 2006). The exact biological role of dardarin is not yet known 
(Nuytemans, et al., 2010). LRRK2 is located at 12q12 (Hardy, et al., 2006). It is unclear how this 
gene may cause PD, but it has been shown to be associated with families that have a history of 
late-onset PD (Nuytemans, et al., 2010). It is hypothesized that LRRK2 may have an effect on the 
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phosphorylation of proteins central to PD, such as α-synuclein and Tau, which can be found in 
the protein aggregates called Lewy bodies (Cookson & Bandmann, 2010).  There have been over 
100 mutations in this gene that have been found in families afflicted with PD (Kalinderi, et al., 
2016). 
The parkin RBR E3 ubiquitin protein ligase gene (PARK2), makes the protein parkin 
under normal conditions (Nuytemans, et al., 2010).  This protein has a role in the breakdown of 
other proteins by tagging them with ubiquitin, a signaling molecule designed to move unneeded 
or damaged proteins to the proteasome of the cell, where they are degraded (Nuytemans, et al., 
2010). Studies have also indicated that parkin may have a role in the maintenance of 
mitochondria (Kalinderi, et al., 2016). Most of these mutations lead to the production of 
abnormal parkin protein (Nuytemans, et al., 2010). The loss of parkin activity may affect the 
breakdown of damaged proteins, leading to a buildup of aggregates that can potentially disrupt 
neurons that transmit dopamine (Kalinderi, et al., 2016). The PARK2 gene is located between 
6q25.2 and 6q27 (Nuytemans, et al., 2010).  
The gene Parkinsonism associated deglycase (PARK7) is located on 1p36.23 (Kalinderi, 
et al., 2016). The function of this gene is to make the DJ-1 protein. The DJ-1 protein has several 
functions including the protection of neurons and other cells from oxidative stress, serving as a 
chaperone molecule to assist in protein folding and degradation, and RNA processing (Kalinderi, 
et al., 2016). Although it is unclear how the DJ-1 protein affects PD pathobiology, studies have 
suggested that mutations in the PARK7 gene can cause a breakdown of the chaperone qualities of 
DJ-1, leading to a build up of protein (Hardy, et al., 2006).  Also, the loss of oxidative stress 
protection could affect the neurons that transmit dopamine (Klein & Westenberger, 2012). 
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PTEN induced putative kinase 1 is made by a gene of the same name (PINK1). This 
protein appears to protect mitochondria from malfunctioning during times of stress, when there 
are high energy demands within the cell, although this is not well understood (Brooks, et al., 
2009). There are two different segments of this protein that appear to be vital for basic 
functionality; these are the mitochondrial-targeting motif, which ensures that the protein moves 
to the mitochondria after it is made, and the kinase domain, which performs the protective 
functions (Klein & Westenberger, 2012). Mutations in the PINK1 gene are associated with the 
early-onset form of PD (Brooks, et al., 2009). These mutations work to disrupt or remove the 
kinase domain, which leads to loss of protein function, and eventual cell death. The PINK1 gene 
is located on 1p36 (Klein & Westenberger, 2012). 
The synuclein alpha gene (SNCA) is located on 4q21, and is responsible for making the 
alpha synuclein protein (Nuytemans, et al., 2010) The function of this protein is to supply 
synaptic vesicles within the presynaptic terminals, and also may regulate the release of dopamine 
(Nuytemans, et al., 2010).  The mutations in SNCA can either lead to a misfolded alpha synuclein 
protein, or extra copies of the normal protein (Nuytemans, et al., 2010). The excess amount of 
protein can form aggregates that can impair neuronal function and lead to problems with the 
regulation of dopamine (Klein & Westenberger, 2012). 
The gene glucosidase, beta, acid (GBA) functions to make an enzyme called beta-
glucocerebrosidase, which is a digestive enzyme used to breakdown toxic substances within the 
lysosome of the cell (Blanz & Saftig, 2016). GBA is located on 1q21. Mutations in this gene and 
their association with PD are not yet clear, although it has been proposed that these genetic 
alterations may contribute to lysosomal dysfunction and collection of protein aggregates (Blanz 
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& Saftig, 2016). These genetic changes have also been seen in those with Gaucher disease, and 
individuals with this condition have an increased risk of PD (Blanz & Saftig, 2016).  
Ubiquitin C-terminal hydrolase L1 (UCHL1) is a gene responsible for making an enzyme 
called arboxyl-terminal esterase L1, which is found in nerve cells throughout the brain (Samii, et 
al., 2004). This enzyme has a similar function to beta-glucocerebrosidase, which breaks down 
toxic substances (Samii, et al., 2004). One particular polymorphism in the UCHL1 gene actually 
reduces the risk of developing PD, and this is primarily found in Chinese and Japanese 
populations (Samii, et al., 2004). It is not quite clear by what mechanism this variation affects 
risk. The UCHL1 gene is found on 4p14 (Samii, et al., 2004). 
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3.0 CENTRAL APPALACHIAN HEALTHCARE AND SUPPORT GROUP 
CONSIDERATION 
3.1 HEALTHCARE BURDENS AND DISEASE SIGNIFICANCE IN APPALACHIA  
3.1.1 ACCESS TO HEALTHCARE IN APPALACHIA 
 The Appalachian region of the United States is a region that encompasses the range of the 
Appalachian Mountains in the eastern part of the country (ARC, 2016). It comprises 
approximately 205,000 square miles and contains the entire state of West Virginia, and parts of 
twelve other states: Alabama, Georgia, Kentucky, Maryland, Mississippi, New York, North 
Carolina, Ohio, Pennsylvania, South Carolina, Tennessee, and Virginia (ARC, 2016).  
The differences we see in the demographics, poverty, and healthcare access of the 
Appalachian region contribute to the unique healthcare burdens that these states experience. In 
Appalachia, there is a higher rural population compared to the rest of the United States, (42% 
versus 20%, respectively) (OCC, 2013). Also, the poverty rate is slightly increased above the 
national average (15.4% versus 14.8%) (ARC, 2014). It has also been established that there is a 
healthcare provider shortage in the Appalachian region and this is due in part to the low 
healthcare reimbursement (Lane, et al., 2012). These provider shortages in turn lead to fewer 
clinics and hospitals being opened in the rural areas of Appalachia (Lane, et al., 2012). This is 
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especially an issue for the Appalachian region, as the region as a whole suffers from a higher 
mortality rate due to chronic disease (Halverson, et al., 2004).  
There is also the issue of the low health literacy rate throughout the country (Kutner, et 
al., 2006). Health literacy, defined as “the degree to which individuals have the capacity to 
obtain, process, and understand basic health information and services needed to make 
appropriate health decisions” (Selden, et al., 2000), is a problem throughout the United States.  
Currently, only twelve percent of adults in the United States are considered health literate, and 
those living in lower income areas and among populations that have a lower educational level 
overall, are more at risk to experience low health literacy (Kutner, et al., 2006).  
This lack of health literacy has left its mark on the people of this region. Knowledge 
deficiency often leads to fear of physicians and healthcare procedures, which in turn breeds 
distrust among patients (Behringer, et al., 2006). The poor patient-provider relationship can often 
lead to issues with keeping appointments, medication adherence, poor health behaviors and 
suffering of treatment plans (Liang, et al., 2013). With all of these other factors, it is easy to see 
how the issues of healthcare access in Appalachia stretches far beyond dollars and cents.  
3.1.2 HEALTHCARE ACCESS IN CENTRAL APPALACHIA  
Due to the lack of patient registries and potential under diagnosis it is difficult to 
determine the significance of the four adult-onset neurological disorders outlined above in 
central Appalachia. However, due to the provider shortage that this region is suffering from 
(Lane, et al., 2012), and given that these disorders also have fairly generalized symptoms that 
can easily be overlooked and misdiagnosed, (Bates et al., 2015; NINDS, 2013; NIA, 2015; 
 31 
Samii, et al., 2004), it stands to reason that there may be many undetected cases of these diseases 
throughout the region.  
Because of the attributes of these disorders and the provider shortage in this region the 
disparities already experienced by these populations are more emphasized. The healthcare 
burdens faced by patients and family members who are affected by disease are numerous in 
nature (Halverson, et al., 2004).  Because these individuals may have limited access to basic 
healthcare needs, as well as patient and caregiver support, these patients may face a more 
difficult time with their diagnosis and treatment (Lane, et al., 2012). To address access to patient 
and caregiver support groups, an assessment of current services followed by comprehensive 
research to determine patient needs should be completed, and then be used to provide services 
and support in an economically and geographically sound way that makes sense for the given 
region.  
3.2 SUPPORT GROUP EXPLORATION 
3.2.1 BENEFITS AND DRAWBACKS OF SUPPORT GROUPS 
 Support groups are important to those afflicted with long term chronic illness because 
they provide a forum for social interaction, peer support, and discussion of the illness in question 
(Locock & Brown, 2010). These groups are also important for the caretakers involved with those 
who have diseases, as the lifestyle and duties of caretakers can produce a great deal of stress, 
which can in turn affect the patient (Schulz & Martire, 2004). The benefits and harms to the 
patients and caretakers involved in disease support groups rests on the individuals (Locock & 
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Brown, 2010), but may also be due to the participants, and the organization and professionals 
facilitating the support groups. The effects of support groups rest heavily on social comparison 
theory, in which an individual has a drive to gain accurate self-evaluations and awareness, by 
drawing comparisons to others with their predicament (Locock & Brown, 2010).  
For those who suffer from disease, especially diseases that can produce cognitive or 
psychiatric symptoms, emotions play a rather large role in treatment and management (Attard & 
Coulson, 2012). This is a fickle aspect of support groups, as some people may derive benefits 
from them, while in others, social support may beget emotional harms (Locock & Brown, 2010). 
Many benefits of support groups have been studied using questionnaires disseminated to patients 
and family members affected with various health conditions (Ziebland & Wyke, 2012), some of 
which can include: information exchange, the sharing of experiences, social connection, 
increased optimism, improved emotional well-being, and potentially better disease management 
and health outcomes (Mo & Coulson, 2014).  
In contrast to this, based on interviews of 48 patients with Motor Neuron Disease and 22 
caregivers, followed by literature review and analysis, it was found that support groups can foster 
negative effects such as the fear of meeting others, fear of interaction, fear of judgment, 
misinformation regarding the disease, and potential damage to the patient-provider relationship 
(Locock & Brown, 2010). Again, drawing from social comparison theory, a patient may also 
begin to identify as just a person with a disease, and thus, sense of self can eventually be lost 
(Locock & Brown, 2010). 
These benefits and harms can also change depending on the environment of the support 
group in question. With the advent of the Internet, online support groups for both patients and 
caretakers have blossomed, especially for long term or chronic illness (Coulson, et al., 2007). 
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Patients or caregivers often choose online support groups for the same reasons that they would 
choose in-person groups, but there are benefits that in-person groups cannot provide, such as 
connecting with a large amount of people from around the world, as well as the benefit of being 
anonymous (Mo & Coulson, 2014). However, with new advances in healthcare technology, there 
are almost always some shortcomings unique to the specific advance that should be improved 
upon.  
Some of the disadvantages of online disease support groups include: unidentifiable 
presences online, inappropriate behaviors, risk of personal information being detected and stolen, 
over exaggerated claims, information overload, and misinformation (Malik & Coulson, 2010). 
Apart from these distinctive limitations, there is also the major problem of the impersonal nature 
of the Internet (Mo & Coulson, 2014). The inability to connect physically to another person or 
groups of people can be a major setback for all patients, but particularly for those who do not 
feel important or heard by others, which can lead to increased anxiety and depression (Mo & 
Coulson, 2014). Another issue with online support groups is attendance because many people 
tend to drop out of these groups whether it is due to a loss of interest, loss of connectivity, or 
simply life getting in the way (Sandaunet, 2008).  
Another problem with online support groups is the specific demographics that can fall by 
the wayside, such as older populations. In a study involving 230 adults diagnosed with lung 
cancer, it was found that online support groups are more conducive to younger populations (Xu, 
et al., 2013).  It was also found that older generations are less likely to use online resources due 
to a lack of knowledge, as well as habitual practices of having in person interaction (Xu, et al., 
2013). This study used questionnaires disseminated to participants to gather data, and this data 
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organized predisposing, enabling, and need factors across various demographics (Xu, et al., 
2013). 
Another problem with online support groups is the specific demographics that can fall by 
the wayside. Online support groups are more conducive to younger populations, and those that 
can afford an Internet connection (Xu, et al., 2013). Older generations are less likely to use 
online resources due to a lack of knowledge, as well as habitual practices of having in person 
interaction (Xu, et al., 2013). Those in economically disadvantaged areas may not believe they 
are able to afford an Internet connection, may not put high importance on it, or may not want to 
invest in technology (Porter & Donthu, 2006).  
The positive aspect of online support groups is that they often have the same outcomes 
that in person meetings produce. A study assessing 1,313 messages for evidence of social 
support accessed via a public Huntington disease support message board showed that online 
support groups for both patients and caretakers reduce anxiety and give them a medium in which 
they can communicate and draw support (Coulson, et al., 2007).  While information overload and 
misinformation can be a problem in online communities, the plethora of information and sources 
online lends a good deal of support and opportunities to learn about disease management and 
new treatments (Attard & Coulson, 2012).    
3.2.2 SIGNIFICANCE OF SUPPORT GROUPS FOR NEUROLOGICAL DISORDERS 
Having more support groups that cater to patients and caretakers of Huntington’s disease, 
Amyotrophic lateral sclerosis, Alzheimer’s disease, and Parkinson’s disease play an important 
role in disease management and social support, as evidenced by prior work (Attard & Coulson, 
2012; Coulson, et al., 2007; Schulz & Martire, 2004; Locock & Brown, 2010). The unique 
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aspects of these neurological conditions include the cognitive and psychiatric symptoms present 
in these disorders, the progressive, sometimes fatal nature of the disease, the associated genetic 
attributes, and the prevalence throughout the United States. Due to these qualities, support 
groups may fulfill the needs and improve the lives of patients, families, and caretakers afflicted 
by the four disorders characterized in this essay.  
Coping with a disease that often results in loss of cognitive functions and the initiation of 
psychiatric disorders can be extremely difficult. Caretakers of these patients must go through the 
rigors of these symptoms with the patient, which can and does take a deep emotional toll on them 
(Schulz & Martire, 2004). Having support groups available to both the patient and caretaker can 
be important to helping them remain emotionally steadfast and mentally capable as long as it is 
possible or necessary (Schulz & Martire, 2004). Support groups have been identified by patients 
to be socially stimulating, helpful in managing day-to-day tasks, and integral to their self-esteem 
(Locock & Brown, 2010).  
Often, due to the rapid progression of some neurological disorders such as Huntington’s 
disease, patients will experience high levels of stress and anxiety (Coulson, et al., 2007). Many 
support groups for diseases such as this will frequently discuss stress and disease management, 
and social support for patients who feel as though no one can understand their experiences 
(Coulson, et al., 2007). Having access to both information and support is critical for the well-
being of the patient, as learning about and utilizing new treatments and management techniques 
can reduce symptoms and perhaps prolong life expectancy (Mo & Coulson, 2014). 
The low prevalence of these neurological conditions could also have an effect on the 
amount of information available, as well as access to healthcare specialists that work with these 
disorders. This can lead to decreased availability of support groups, due to the lack of trained 
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individuals available to moderate them, especially in the rural areas of the United States, where 
hospital and physician shortages already exist. Of course, support groups can never replace the 
role of hospital facilities and medical care that patients need. However, if more support groups 
are available within rural areas, physicians, nurses, therapists, and genetic counselors would have 
an additional way to reach out to these patients and could perhaps use support groups as an 





4.1 DATA SOURCING  
 In determining the number and locations of disease support groups for the four 
neurological conditions outlined previously, I used an online search engine query using Google 
to find the primary organizations that facilitated in-person support groups for each disorder.  An 
example of a phrase used in the search was “Huntington disease support groups”. My queries 
tabulated many search results; however, many of these results often linked back to national 
organizations offering a variety of resources, and this occurred for each disease. I chose to use 
one organization for each of the four neurological diseases in order to best compare the support 
availability for each disorder, as some diseases had multiple organizations to choose from, 
whereas others had only one or two organizations that offered support groups. I chose the 
organizations based on the amount of data present on each website, and on the number of support 
groups that the website listed. Although patient and caregiver support groups operated by local 
organizations or private citizens exist, assessing and comparing the number of these that are 
available for each state and each disease is difficult, primarily because they are not as accessible 
via online searches. Because part of my goal was to determine how patients and caregivers 
identify resources, I focused on the national organizations 
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The organizations that I chose were The Huntington’s Disease Society of America, The 
ALS Association, The National Parkinson Foundation, and The Alzheimer’s Association. Each 
of these organizations had different types of online tools that one could use to locate support 
groups. However, each of these online tools was structured differently. Some of these websites 
required an input of an address or area code and the nearest support groups were shown based on 
a chosen mileage, while some simply gave a listing of all support groups available within each 
state. The structures of these online tools are detailed below in Table 1. The exact number of 
support groups per city was difficult to determine from the organization data, given that entire 
regions of some states were missing. Therefore, I used towns and cities that had available 
support groups in them to determine county-level data.  
 
Table 1: Support Group Organization Listing and Online Tool Description 
 
Disease  Organization  Online tool description  
Huntington disease Huntington’s Disease Society of America 
http://hdsa.org/about-hdsa/locate-
resources/ 
Address or area code input and distance 
indicator (25-1000 miles); also 
included interactive map with locations 
of support groups indicated  
Parkinson disease The National Parkinson Foundation  
http://www.parkinson.org/find-
help/resources-in-your-community 
Area code input or state selector can be 
used in tandem with a distance 
indicator (10-250 miles) and a selection 
of PD Care or Community 
Organizations is offered; when 
selections are made, a list of 
community organization that offer 
support services is tabulated  




State selector available; once a state 
was chosen, a list of organization 
chapter websites given, which linked to 
a tabulated listing of support groups 
offered by the chapter 
Alzheimer disease The Alzheimer’s Association  
http://www.communityresourcefinder.org/ 
 
Address or area code input or name 
input along with other search options 
such as date of event, delivery, 
audience served, language; a listing of 
support groups with locations, dates, 




To determine the county that each support group is located in, I performed a Google 
search of each city or town indicated in the support group location information. Next, I used the 
Appalachian Regional Commission webpage (ARC, 2016), which contains a listing of counties 
in Appalachia for each state that falls within the Appalachian region to determine if a county was 
located in the defined Appalachian region of the United States.  
Using the Appalachian Regional Commission webpage, I determined each Appalachian 
county’s economic status. The Appalachian Regional Commission uses an index-based county 
economic classification system to determine a county’s status. This system uses three economic 
indicators to compare counties to the national averages. These indicators are three-year average 
unemployment rate, per capita market income, and poverty rate. The counties are then ranked by 
different levels of economic distress level based on a composite index value assigned to the 
county by this comparison. The levels of economic distress are: distress (worst 10 percent of the 
nation's counties), at-risk (between the worst 10 percent and 25 percent of the nation's counties), 
transitional (between the worst 25 percent and the best 25 percent of the nation's counties), 
competitive (between the best 25 percent and the best 10 percent of the nation's counties are 
classified competitive), and attainment (best 10 percent of the nation's counties are classified 
attainment) (ARC, 2014).  
4.2 DATA ANALYSIS  
 I used Microsoft Excel for data entry and analysis and created a worksheet for each 
disease and listed the number of support groups for each state, their town or city location, the 
county that the location was in, and the economic status of each county. I then determined the 
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total number of counties represented by support group availability in each state, as well as the 
number of Appalachian counties, and the number of economically distressed or at risk counties 
in Appalachia. I then split this Excel workbook into two separate workbooks, one for 
Appalachian counties and one for the total number of counties with support groups. I arranged 
this information into bar charts organized by state and disorder to produce a visual representation 
of the descriptive statistics of support groups for each disease by state (See Figures 4 and 5). 
I tabulated the total number of counties with and without support groups (across all four 
diseases) for each of the six states   (Table 2). Within each state, I also tabulated the number 
Appalachian counties with and without support groups, as well as the number of non-
Appalachian counties with and without support groups (Table 3).  To assess whether distressed 
counties had fewer support groups than non-distressed counties within Appalachia, I also 
compiled, by state, the number of distressed counties with and without support groups and the 
number of non-distressed counties with and without support groups (Table 4).  
 To test for differences in numbers of support groups between Appalachian and non-
Appalachian counties, and between distressed versus non-distressed counties, I performed chi-
squared tests.   Calculations were done in Microsoft Excel using the function =chitest.   
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5.0 RESULTS 
5.1 PRESENCE OF SUPPORT GROUPS BY STATE AND APPALACHIAN REGION  
Using online databases (Table 1), a total of 449 counties in six states were assessed to 
determine whether they did or did not contain at least one support group for at least one of the 
four neurological conditions: Huntington Disease (HD), Amyotrophic lateral sclerosis (ALS), 
Parkinson Disease (PD), and Alzheimer Disease (ALZ).  Both patient and caretaker support 
groups were included in the assessment. 
 
 





of counties with 
support groups  
Number (%) of 
counties without 





(1000 sq mi) 
WV 20 (36%) 35 (63%) 1.85 24.2 
PA 24 (36%) 43 (64%) 12.79 46.1 
KY 27 (23%) 93 (77%) 4.41 40.4 
MD 19 (79%) 5 (21%) 5.98 12.4 
OH 51 (58%) 37 (42%) 11.59 44.8 
VA 73 (77%) 22 (23%) 8.33 42.8 





Across the six states, the number of counties varied widely from 24 in MD to 120 in KY 
(Table 2).  The difference in the number of counties among the states was not related to the size 
of the population of the area.  Across the six states, the proportion of counties with at least one 
support group ranged from 23% in KY to 77% in VA.  However, over all states (Table 2), the 
proportion of counties with support groups (48%) was comparable to the proportion of counties 
without support groups (52%),  
 The following clustered column charts illustrate the difference of the number of support 































From this data, a disparity can clearly be seen regarding location of support groups. Some 
states do not have support groups for all diseases within Appalachia, forcing those who do live in 
this region to travel to utilize these in person resources. This regional disparity can be more 
clearly seen in Figure 5, which compares the total number of counties with support groups 
throughout a state (blue) with the number of counties in the Appalachian regions of a state with 
support groups (red). The support groups for each condition are combined in this graph for visual 




















One of the goals of this essay was to assess whether the number of support groups 
available in Appalachian counties differs from the number of support groups in non-Appalachian 
counties. Across all states, the proportion of counties with support groups was lower within 
Appalachian regions compared to the non-Appalachian regions, 34% versus 61%, respectively 
(Table 3). However, these proportions differ by state. In West Virginia, Maryland, and Ohio, the 
proportion of counties with support groups is higher within the Appalachian regions than outside 
the Appalachian region (Table 3).  These results are skewed for West Virginia and Maryland 
because all of the counties in West Virginia are within the Appalachian region, whereas only 
three counties in Maryland are in Appalachia. For the other three states, the proportion of 
counties with support groups is lower in the Appalachian region versus the non-Appalachian 
Figure 4: Comparison of Support Groups Availability: Total State Counties and 
Appalachian Region Counties 
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region (Table 3).  Thus, among these six states, Ohio may be the only one that has similar 
support group representation both in and out of the Appalachian counties. 
 
Table 3: Appalachian and Non Appalachian Counties with Support Groups Present and Absent Represented 




















WV 20 (36%) 35 (64%) 0 (0%) 0 (0%) 
PA 15 (29%) 37 (71%) 9 (60%) 6 (40%) 
KY 7 (13%) 47 (87%) 20 (30%) 46 (70%) 
MD 3 (100%) 0 (0%) 16 (76%) 5 (24%) 
OH 21 (67%) 11 (33%) 30 (54%) 26 (46%) 
VA 9 (36%) 16 (64%) 64 (91%) 6 (9%) 
Total 75 (34%) 146 (66%) 139 (61%) 89 (39%) 
 
I next tested whether the number of Appalachian counties with at least one support group 
differed from the number of non-Appalachian counties with at least one support group (Table 4). 
As can be seen, the proportion of counties (34%) with support groups is statistically significantly 
lower in Appalachian counties compared to the proportion of counties (61%) outside of this 
defined region (Χ2 = 32.86, 1 df, p value = 9.881 x 10-9 ).  
 
Table 4: Chi Square Analysis Table (Appalachian Counties and Non Appalachian Counties) 
 





Appalachian Counties 75 (34%) 146 (66%) 221 
Non-Appalachian 
Counties 139 (61%) 89 (39%) 228 




5.2 PRESENCE OF SUPPORT GROUPS IN APPALACHIAN REGION BY ECONOMIC 
STATUS 
Most of the support groups were located in major metropolitan areas, and very few of 
these metropolitan areas were close to counties in Appalachia. I determined the urban 
(metropolitan) and rural classification of the counties by using the most updated listing of the 
Rural-Urban Continuum Codes provided by the United States Department of Agriculture 
Economic Research Service, which classifies counties by population and proximity to 
metropolitan areas. These codes classify all counties within the United States and organize them 














 Figure 5: Rural-Urban Continuum Code Description for County Categorization (Parker, 2013) 
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The proportion of counties within Appalachia that do or do not contain support groups by 
economic status (distressed or non-distressed) was assessed to answer the question: “Is the 
economic status of the Appalachian county associated with the presence or absence of support 
groups?  Overall, the proportion of counties with support groups is lower for economically 
distressed counties (19%) versus economically non-distressed counties (46%) in Appalachia  
When examined on a state-by state basis, this trend applies to every state except Ohio (Table 5).   
This overall difference in proportions between economically distressed and non-distressed 
counties was statistically significant (Χ2 = 17.39, 1 df, p-value = 3.043 x 10-5  ). 
 
 
Table 5: The Number (Percent) of Distressed and Non Distressed Counties in Appalachia With and 

















WV 5 (21%) 19 (79%) 15 (48%) 16 (52%) 
PA 0 (0%) 1 (100%) 15 (29%) 36 (69%) 
KY 5 (10%) 45 (90%) 2 (50%) 2 (50%) 
MD 0 (0%) 0 (0%) 3 (100%) 0 (0%) 
OH 9 (69%) 4 (31%) 12 (63%) 7 (37%) 
VA 0 (0%) 11 (100%) 9 (64%) 5 (36%) 





Table 6: Chi Square Analysis Table (Distressed Counties and Non Distressed Counties in 
Appalachia) 





Distressed Counties 19 (19%) 80 (80%) 99 
Non-Distressed Counties 56 (46%) 66 (54%) 122 
Total 75 146 221 
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These results indicate that a significant disparity may exist regarding the availability of 
support groups in the Appalachian regions of these states.  Furthermore, the availability of 
support groups is lower in the distressed counties of the Appalachian region of these states. The 
only state that had approximately equal availability of support groups in and out of Appalachia 
was Ohio, but the reasons for this difference are unclear.   Nevertheless, more research should be 
done to further assess these apparent disparities.  
6.0 DISCUSSION 
6.1 PUBLIC HEALTH SIGIFICANCE OF SUPPORT GROUPS  
The results of the online search for local support groups of the four national support 
organizations examined in this essay (see Table 2 and Figures 5-7) suggest that there may be a 
need for more support groups for these disorders in the Appalachian region of the United States, 
particularly in distressed and at-risk counties.  While the results do seem to indicate disparities 
between the amount of support groups found in Appalachian counties compared to non 
Appalachian counties, and the amount of support groups in economically distressed Appalachian 
counties compared to non distressed Appalachian counties, there could be barriers that are 
limiting support group availability in these areas. These include: lack of resources, lack of 
facilitators, a smaller number of people that are affected with these disorders, or those who may 
not feel as though they need support groups. Ohio was the state that seemed to be significantly 
different, indicating that there is a more equal distribution of support groups throughout the 
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counties. Every state is different of course, but examining the state of Ohio more thoroughly 
could be useful in learning lessons about support group distribution.  
The four neurological disorders considered in this essay are ideal examples of patient and 
caregiver populations that may benefit from support groups due to the progressive nature of the 
diseases, the resulting loss of normal functionality, the lack of research on the prevalence and 
incidence of some of these disorders, and the genetic features of each disease. Support groups 
can be a helpful resource to both patients and caretakers, and while there may be online support 
groups and other resources that they can utilize, having the option of in-person support groups 
should be an option for those who may not be comfortable with online environments, those who 
would like more personal interaction, those who do not have access to the internet, and those 
who are worried about online safety (Malik & Coulson, 2010; Xu, et al., 2013). 
Disease awareness is an issue of major public health significance.  It is the opinion of the 
author that support groups serve to exemplify two of the ten essential services of public health, 
which are 1) “To inform, educate, and empower people about health issues,” and (2) “Link 
people to needed personal health services and assure the provision of health care when otherwise 
unavailable” (CDC, 2013). Disease support groups can act as forums that can be used to educate 
patients, caregivers, and families about the disease, and also to help make disease management 
better, by promoting connections to other people going through similar circumstances (Locock & 
Brown, 2010; Mo & Coulson, 2013).  Through education and empowerment, support groups can 
provide group members with more information about various therapies as well as foster 
partnerships with healthcare professionals, which may lead to better care (Mo & Coulson, 2013). 
Though support groups can potentially exemplify another essential service of public health, 
which is mobilizing community partnerships and action to identify and solve health problems, 
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(CDC, 2013), there has not been sufficient research performed in this area to show that support 
groups truly provide this service.  
For future actions to be taken on the subject of support group placement in central 
Appalachia, more comprehensive research is needed. If future research suggests a disparity, then 
a needs assessment can be performed in this region to determine if and/or how support groups 
would meet the needs of Appalachian communities. A needs assessment is public health tool that 
determines and analyzes a gap or a “need” that exists between current conditions and desired 
outcomes (Grant, 2002). This gap is something that must be measured before any public health 
intervention can take place (Grant, 2002). 
6.2 ETHICAL CONSIDERATIONS OF SUPPORT GROUP PLACEMENT 
After reviewing the information about support group locations presented in this essay, 
one may question why there is a disparity that exists in support groups, and why they are placed 
more often in metropolitan areas. There could be many good reasons for the placement, such as 
proximity to hospitals and health care providers, placement in areas that are more populous, and 
placement in areas where vital services for patients are available, but this is speculation. While 
support groups are needed in major metropolitan areas for these reasons and more, there could 
potentially be many patients in more rural areas such as Appalachia that are not getting to 
experience the benefits that these groups can provide.  
When considering healthcare ethics and disease support groups, the ethical principles of 
autonomy, beneficence, and justice can play a role. The concept of beneficence refers to an 
action, or idea that benefits another person or group of people (Beauchamp, 2013). There is 
evidence that support groups help both patients and caretakers (Locock & Brown, 2010; Mo & 
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Coulson, 2013). The true relation between the principle of beneficence and support groups has 
more to do with ensuring that these services are located in areas where they are needed and can 
be easily accessed.  
Furthermore, beneficence must be a guiding principle for facilitators of support groups to 
ensure to the best of their abilities that the groups act to benefit participating patients and 
caregivers. There are a number barriers that can affect the location of support groups, such as a 
lack of facilitators, a small number of individuals affected by a particular condition in specific 
areas, or a lack of interest in a support group by affected individuals, their caregivers, and/or 
their family members in a specific area. While these barriers are often outside of the control of 
national support organizations, healthcare facilities, or group facilitators, it would be important 
to carefully consider approaches that would allow support groups to benefit as many people as 
possible.  
Autonomy is defined as “the measure of the person's independence from influences 
that control the person's preferences, thoughts, and behavior” (Beauchamp, 2013). Promoting 
patient and caregiver autonomy is very important, and support groups can help to do this by 
providing education, knowledge of resources, and social support from others in a similar 
situation (Locock & Brown, 2010; Mo & Coulson, 2013). A patient or a caregiver who is 
knowledgeable about a condition and the resources that are available to them may gain additional 
autonomy in managing and treating that condition.  
Justice is also an ethical principle that is important in support group placement. Justice 
means that there is an equal allocation of resources and their benefits, as well as burdens. A limit 
of face-to-face support groups and the fact that support groups are not available in every 
community may lead to patients and caregivers feeling that their choices are limited. The 
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addition of more online support groups may help, but only one organization for the four 
disorders facilitated online support groups directly, and with the dangers that online support 
groups can impose, (Malik & Coulson, 2010) it may be better if online groups were organized 
and monitored by organizations and sources that patients and caretakers can trust, like the four 
organizations that are discussed in this essay. However, the barriers described above still exist 
and more research on these location-based barriers and the methodology of support group 
placement is needed, though the preferences of support group participants should also be 
considered.  
6.3 LIMITATIONS 
This study has several limitations. One of the primary detriments was the general lack of  
epidemiologic information about the diseases. There is limited data on the prevalence and 
incidence rate for all four neurological conditions discussed in this paper. This limitation may be 
due to underreporting or under diagnosis of the diseases, as well as limited education of both 
patients and healthcare professionals. Another limitation is the lack of research on disease 
support groups for genetic neurological diseases. Although information regarding the 
experiences of support groups for other diseases is useful, these neurological disorders are 
unique, and the same benefits and drawbacks of support groups may not be similar.   
 There was also a lack of information in certain aspects of the support group investigation. 
The organizations that provided the support group locations may not have always had an updated 
website or the best online search tools, and this could have lead to discrepancy in the number of 
support groups in each state or the counties that were represented in each state. I also did not take 
into account support groups that are operated by other organizations on a national, state or local 
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level, or those operated by private citizens. While some disorders had multiple national 
organizations that facilitated support groups (Parkinson disease), others had one primary national 
organization that did the same (Huntington disease). The organizations that might have 
facilitated support groups on a state, local, or private level were difficult to identify and assess, 
therefore, for consistency across disorders, I decided to compare data obtained from one national 
organization for each disorder  
 Discrepancies may have also occurred when information was gathered on the different 
counties and their economic status. When examining different states, there also must be a 
consideration of how a state divides up cities and towns into counties. Some cities are located 
entirely within one county, whereas others may encompass multiple counties.  These counties 
can of course have different economic statuses. The economic status of the counties and the 
population sizes of the counties also may not be up to date. Furthermore, I did not assess the 
number of support groups per capita, based the state (or county) population, nor did I assess the 
support groups by geographic area (of counties, cities, etc).  These limitations , also may  affect 
the results.  
 The various differences between the states and their Appalachian region counties was 
also a limitation in regards to the research findings of this study. Some states had a majority of 
their counties as located within the Appalachian region, while other states had very few counties 
in Appalachia. This difference may have affected the findings listed in the investigation 
discussion in regards to the differences between the number of counties with support groups 
within Appalachia versus the number found statewide.  
 Finally, I did not include the entire Appalachian region of the United States. Data on 
these additional states might have had an effect on the research findings listed in this essay. More 
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research that includes all states of the Appalachian region is necessary before actionable 
conclusions can be drawn. 
6.4 RECOMMENDATIONS 
The purpose of this essay was to examine a potential disparity in the locations of patient 
and caretaker support groups for progressive, neurological disorders with genetic components, 
available through four major, national support organizations specific to these conditions. 
Drawing data from the Appalachian region of the United States, and choosing to focus on central 
Appalachia, provided important information regarding differences in access tosupport groups 
that exists between economically privileged and distressed areas of the Appalachian region. 
From the information and data presented in this essay, this disparity does seem to exist in some 
regard with only 33% of Appalachian counties overall having support groups and only 19% of 
distressed Appalachian counties having support groups. Noting the many benefits of support 
groups, and the integral part that this resource can play in disease management, there should be 
more research and potentially a needs assessment done for central Appalachia to determine if a 
discrepancy truly does exist and if there is a public health need for support groups for individuals 
with these disorders. If an established need does exists, a focus group investigation of patient and 
caretaker support groups similar to the basic focus group investigation described in the Appendix 
should be undertaken. 
Including supplements to formal healthcare services such as support groups can provide 
valuable information, and empower participants to help themselves and their caretakers to cope 
with aspects of progressive disease. Today, the importance of patient centered care cannot be 
overlooked in the United States. Healthcare services that promote patient involvement will 
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become useful to strengthen the patient-provider relationship, and to promote the well-being of 





















APPENDIX: PROPOSED FOCUS GROUP INVESTIGATION 
A.1: INVESTIGATION GOAL 
This is a proposed project to conduct focus groups on participant opinions about adult-
onset neurological disease support group implementation in the Central Appalachian region of 
the United States. The project will focus on four diseases: Huntington disease (HD), 
Amyotrophic lateral sclerosis (ALS), Alzheimer disease (AD), and Parkinson disease (PD). The 
states of the Appalachian region that will be included in this project will be West Virginia, 
Pennsylvania, Ohio, Kentucky, Maryland, and Virginia. The goal of this investigation will be to 
gain insight on the level of support available for these disorders, participant perceptions and 
opinions of support groups, and the type(s) of support groups that they would prefer. This project 
aims to gather information on disease support groups that could possibly be utilized in the 
establishment of new support groups, and to inform the actions of stakeholders. The stakeholders 
of the project are patients, families of patients, caregivers of patients, healthcare providers, 
disease organizations that facilitate support groups, and government entities such as the local and 
state health departments. The questions below were developed based on my prior focus group 
facilitating experience.  Audio recordings from each focus group would be transcribed, themes 
identified, and reports created to be disseminated to stakeholders.   
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A.2: FOCUS GROUP OUTLINE 
 There will be a focus on each state for this project, given that every state has different 
populations, and different healthcare needs. There will be thirty focus groups, five per state 
taking part in the most Appalachian region of the given state. The focus groups will last two 
hours, and will be composed of 8-10 participants with two moderators. These moderators will be 
public health specialists who have experience moderating focus groups, and are familiar with the 
aspects of the diseases as well as the benefits and drawbacks of support groups.  
 The participants will include affected patients, the families of affected patients, and the 
caretakers of affected patients. It is understood that families and caretakers may be one in the 
same, and this will be an important dynamic to assess during the sessions The participants will 
be recruited through advertisements in local healthcare facilities, health departments, nursing 
facilities and local areas of interest that are highly populous, such as grocery stores and churches. 
The advertising will be in print and Internet medium. The funding for the project may come from 
a variety of sources including but not limited to, health departments, organizations for each 
disease, or national and regional organizations such as the Center for Disease Control and 
Prevention or the Appalachian Regional Commission. This information can be used to further 




A.3: FOCUS GROUP QUESTIONS 
 One goal of this focus group project is that each participant has the ability and the 
opportunity to have their opinions heard, all within a timely manner for others participating in 
the groups. Therefore, the following open-ended, non leading questions will be asked of the 
participants, in no particular order.  
 
Do you feel that you have adequate support in this area in managing your illness, the 
illness of your family member, or patient? 
 
What is your perception of disease support groups? 
 
Do you feel that a support group would be helpful to you? 
 
How would you describe the ideal support group to for your needs? 
 
Would you prefer to meet in person with a support group or use online support groups?  
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